Matthew Brougham. Show Affiliations »
Abstract
Mesh: See more » Cost-Benefit AnalysisDrug CostsDrug Industry/economicsNew Zealand
Year: 2007 PMID: 17703014 PMCID: PMC1949446 DOI: 10.1136/bmj.39296.765903.3A
Source DB: PubMed Journal: BMJ ISSN: 0959-8138